# US 2024/0200141 A1 · Covalent chemistry enables extracellular vesicle purification on nanosubstrates ? toward early detection of hepatocellular carcinoma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0200141 A1
- Document ID: US20240200141A1
- Status: Published application
- Kind: A1
- Application number: 17/915,071
- Filed: 2021-03-06
- Published: 2024-06-20
- Earliest claimed: 2020-03-27
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Hsian-Rong Tseng; Yazhen Zhu; Na Sun; Vatche G Agopian
- Web page: https://patentgrep.com/patent/US20240200141A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/57585: {involving compounds identifiable in body fluids}
- C12Q 1/6844: Nucleic acid amplification reactions
- C12Q 1/6883: for diseases caused by alterations of genetic material
- G01N 33/57525: of the liver or pancreas
- C12Q 1/6804: Nucleic acid analysis using immunogens (immunoassay G01N33/53)
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Methods for selectively capturing an extracellular vesicle (EV) from a sample. including the steps of: functionalizing a capture agent for the EV with a first molecule from a first bioorthogonal functional group such that the capture agent remains attachable to the EV and the first molecule is also able to bond to a second molecule from a second bioorthogonal functional group. the second molecule being complementary to the first molecule: mixing the functionalized capture agent with the sample such that the functionalized capture agent binds to the EV and such that an activated sample is formed: functionalizing a capture surface with the second molecule: and depositing at least a portion of the activated sample on at least a portion of the functionalized capture surface to thereby selectively capture the EV by binding of the second molecule with the first molecule.

## Claims

### Claim 1

A method of selectively capturing an extracellular vesicle (EV) from a sample, comprising:
functionalizing a capture agent for said EV with a first molecule from a first bioorthogonal functional group such that said capture agent remains attachable to said EV and said first molecule is also able to bond to a second molecule from a second bioorthogonal functional group, said second molecule being complementary to said first molecule;
mixing said functionalized capture agent with said sample such that said functionalized capture agent binds to said EV and such that an activated sample is formed;
functionalizing a capture surface with said second molecule; and
depositing at least a portion of said activated sample on at least a portion of said functionalized capture surface to thereby selectively capture said EV by binding of said second molecule with said first molecule,
wherein said first molecule from said first bioorthogonal functional group and said capture agent are present in a molar ratio of between 2:1 to 10:1.

### Claim 2 (depends on 1)

The method of claim 1, wherein said first molecule from said biorthogonal functional group is selected from the list consisting of trans-cyclooctene (TCO), Alkyne, and a cyclooctyne derivative.

### Claim 3 (depends on 2)

The method of claim 2, wherein the cyclooctyne derivative comprises dibenzylcyclooctyne (DBCO) or biarylazacyclooctynone (BARAC).

### Claim 4 (depends on 1)

The method of claim 1, wherein said second molecule from said second biorthogonal functional group is selected from the list consisting of tetrazine (TZ) and azide.

### Claim 5 (depends on 1)

The method of claim 1, wherein said capture surface comprises a nanostructured surface.

### Claim 6 (depends on 1)

The method of claim 1, further comprising functionalizing a second capture agent for said EV with said first molecule such that said second capture agent remains attachable to said EV and said first molecule is also able to bond to said molecule comprising said second molecule from said second bioorthogonal functional group, and
wherein said second capture agent is distinct from said capture agent.

### Claim 7

A method of assaying for a cancer in a subject comprising:
selectively capturing an extracellular vesicle (EV) from a sample from said subject, said selectively capturing an EV comprising:
functionalizing a capture agent for said EV with a first molecule from a first bioorthogonal functional group such that said capture agent remains attachable to said EV and said first molecule is also able to bond to a second molecule from a second bioorthogonal functional group, said second molecule being complementary to said first molecule;
mixing said functionalized capture agent with said sample such that said functionalized capture agent binds to said EV and such an activated sample is formed;
functionalizing a capture surface with said second molecule; and
depositing at least a portion of said activated sample on at least a portion of said functionalized capture surface to thereby selectively capture said EV by binding of said molecule with said first molecule;
releasing said EV from said capture surface;
assaying a nucleic acid sequence from said EV; and
determining from said assaying of said nucleic acid sequence from said EV whether said cancer is present in said subject,
wherein said first molecule from said first bioorthogonal functional group and said capture agent are present in a molar ratio of between 2:1 to 10:1.

### Claim 8 (depends on 7)

The method of claim 7, wherein said first molecule from said biorthogonal functional group is selected from the list consisting of trans-cyclooctene (TCO), Alkyne, and a cyclooctyne derivative.

### Claim 9 (depends on 8)

The method of claim 8, wherein the cyclooctyne derivative comprises dibenzylcyclooctyne (DBCO) or biarylazacyclooctynone (BARAC).

### Claim 10 (depends on 7)

The method of claim 7, wherein said second molecule from said second biorthogonal functional group is selected from the list consisting of tetrazine (TZ) and azide.

### Claim 11 (depends on 7)

The method of claim 7, wherein said capture surface comprises a nanostructured surface.

### Claim 12 (depends on 7)

The method of claim 7, further comprising functionalizing a second capture agent for said EV with said first molecule such that said second capture agent remains attachable to said EV and said first molecule is also able to bond to said molecule comprising said second molecule from said second bioorthogonal functional group, and
wherein said second capture agent is distinct from said capture agent.

### Claim 13 (depends on 7)

The method of claim 7, wherein said releasing said EV from said capture surface comprises use of a cleaving agent.

### Claim 14

A method of assaying for a cancer in a subject comprising:
selectively capturing a plurality of extracellular vesicles (EVs) from a sample from said subject, wherein each extracellular vesicle (EV) of said plurality of EVs is selectively captured comprising:
functionalizing a capture agent for an EV of said plurality of EVs with a first molecule from a first bioorthogonal functional group such that said capture agent remains attachable to said EV and said first molecule is also able to bond to a second molecule from a second bioorthogonal functional group, said second molecule being complementary to said first molecule;
mixing said functionalized capture agent with said sample such that said functionalized capture agent binds to said EV and such an activated sample is formed;
functionalizing a capture surface with said second molecule; and
depositing at least a portion of said activated sample on at least a portion of said functionalized capture surface to thereby selectively capture said EV by binding of said molecule with said first molecule;
releasing said plurality of EVs from said capture surface;
assaying a plurality of nucleic acid sequences from said plurality of EVs;
creating an expression profile of said plurality of nucleic acid sequences, said expression profile comprising a quantification of each of said plurality of nucleic acid sequences;
comparing said expression profile with a control; and
determining from said comparing of said expression profile with said control whether said cancer is present in said subject,
wherein said first molecule from said first bioorthogonal functional group and said capture agent are present in a molar ratio of between 2:1 to 10:1.

### Claim 15

A kit for selectively capturing an extracellular vesicle (EV) from a sample, comprising:
a capture agent comprising a first molecule from a first bioorthogonal functional group;
a substrate comprising a functionalized capture surface having a second molecule from a second bioorthogonal functional group, said second molecule being complementary to said first molecule;
a cleaving agent;
instructions for mixing said capture agent with said sample such that said capture agent binds to said EV and such that an activated sample is formed;
instructions for depositing at least a portion of said activated sample on at least a portion of said functionalized capture surface to thereby selectively capture said EV by binding of said second molecule with said first molecule; and
instructions for using said cleaving agent to release said EV from said capture surface,
wherein said first molecule from said first bioorthogonal functional group and said capture agent are present in a molar ratio of between 2:1 to 10:1.

### Claim 16 (depends on 15)

The kit of claim 15, wherein said first molecule from said biorthogonal functional group is selected from the list consisting of trans-cyclooctene (TCO), Alkyne, and a cyclooctyne derivative.

### Claim 17 (depends on 16)

The kit of claim 16, wherein the cyclooctyne derivative comprises dibenzylcyclooctyne (DBCO) or biarylazacyclooctynone (BARAC).

### Claim 18 (depends on 15)

The kit of claim 15, wherein said second molecule from said second biorthogonal functional group is selected from the list consisting of tetrazine (TZ) and azide.

### Claim 19 (depends on 15)

The kit of claim 15, wherein said capture surface comprises a nanostructured surface.

### Claim 20 (depends on 15)

The kit of claim 15 further comprising a plurality of reagents for a nucleic acid test.
